Skip to main content
. 2023 May 30;93(3):1181–1193. doi: 10.3233/JAD-230167

Table 2.

Wilcox-Test results for pairwise comparisons between all study groups, unadjusted for multiple comparison and adjusted for multiple comparisons (Benjamini & Hochberg)

Vitreous Control Versus AD Versus Versus AD only Versus AD+CTE Versus AD+CTE CTE only Versus AD+CTE AD + CTE
Biomarker only CTE AD+CTE
Median p p # p p # p p # Median p p # p p # Median p p # Median
(IQR) (IQR) (IQR) (IQR)
tTau, pg/mL 167000 0.054* 0.08* 0.04** 0.08* 0.82 0.98 1720000 >0.99 >0.99 0.016** 0.049** 2170000 0.015** 0.049** 194000
(84400–1010000) (1030000–4190000) (27900–6780000) (57700–710000)
n = 8 n = 7 n = 15 n = 9
pTau181, U/mL 102 (55–256) 0.09* 0.28 0.056* 0.28 0.96 0.96 364 (284–446) 0.49 0.59 0.46 0.59 273 (175–435) 0.31 0.59 120 (39.6–410)
n = 8 n = 7 n = 15 n = 9
pTau231, U/mL 2510 (836–9480) 0.28 0.42 0.17 0.33 0.48 0.58 23000 (5610–29000) 0.97 0.97 0.04** 0.13 17800 (1840–36400) 0.04** 0.13 1180 (198–5190)
n = 8 n = 7 n = 14 n = 9
40, pg/mL 484 (363–700) 0.61 0.74 0.15 0.71 0.54 0.74 482 (382–546) 0.24 0.71 0.84 0.84 358 (176–482) 0.52 0.74 458 (245–563)
n = 8 n = 7 n = 15 n = 9
42, pg/mL 29.6 (21.6–43) 0.54 0.64 0.10 0.60 0.32 0.64 30.0 (20.5–31.8) 0.24 0.64 >0.99 >0.99 18.1 (6.02–25.7) 0.48 0.64 30.2 (10.1–33.1)
n = 8 n = 7 n = 15 n = 9
NfL, pg/mL 811 (577–9700) 0.53 0.96 0.80 0.96 0.52 0.96 2640 (1050–2650) 0.96 0.96 0.65 0.96 1730 (714–4750) 0.34 0.96 1130 (99.6–3480)
n = 7 n = 5 n = 14 n = 6
Eotaxin-1, pg/mL 49.8 (39.5–92.1) 0.96 >0.99 0.87 >0.99 0.09* 0.28 66.5 (20.9–115) >0.99 >0.99 0.07* 0.28 54.1 (22.4–162) 0.14 0.28 19.5 (13.5–46.4)
n = 8 n = 7 n = 14 n = 9

p, unadjusted p value; p#, p value after adjusting for multiple comparisons testing. *p < 0.10; **p < 0.05. IQR, interquartile range; AD, Alzheimer’s disease; CTE, chronic traumatic encephalopathy; Aβ, amyloid-β; tTau, total tau; pTau, phosphorylated tau; NfL, neurofilament; pg/mL, picograms per milliliter; U/mL, units per milliliter.